microRNAs在肿瘤表观遗传调控的研究进展

马筱秋; 蔡建春

doi:10.3969/j.issn.1000-8179.2012.04.015

microRNAs在肿瘤表观遗传调控的研究进展

doi: 10.3969/j.issn.1000-8179.2012.04.015

马筱秋¹,
蔡建春^,

厦门大学医学院厦门大学附属第一医院肿瘤外科, 厦门市肿瘤中心（福建省厦门市361003）

基金项目:

福建省自然科学基金面上项目基金 2009D004

详细信息

通讯作者:
蔡建春 jianchunfh2@sina.com

计量
- 文章访问数: 14
- HTML全文浏览量: 2
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2011-10-15
- 修回日期: 2011-11-15

Advances in the Research on the MicroRNAs Related to Tumorous Epigenetic Modifications

Xiaoqiu MA¹,
Jianchun CAI^,

Medical College of Xiamen University, Department of Surgical Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China

Funds:

the Natural Science Foundation of Fujian Province 2009D004

More Information

Corresponding author: Jianchun CAI, E-mail: jianchunfh2@sina.com

摘要

摘要: microRNAs和表观遗传修饰都在肿瘤的发生发展过程中发挥重要作用研究发现microRNAs与表观遗传之间存在复杂的调控关系, 主要通过DNA甲基化和组蛋白修饰等方式与microRNAs进行相互调节, 这为肿瘤的机制研究提供了新的方向。利用表观遗传的可逆性调节相关microRNAs的表达可抑制肿瘤生长, 在肿瘤治疗方面显示出巨大潜力。本文主要综述近年来microRNAs与肿瘤表观遗传相关领域的研究进展。
- microRNA /
- 表观遗传学 /
- 肿瘤 /
- 治疗
Abstract: Both microRNA(miRNA) and epigenetic modifications play crucial roles in tumorigenesis and tumor progression. Scientific findings have revealed that microRNA and epigenetics are intertwined.The mutual interaction between epigenetics and microRNA is carried out mainly through DNA methylation and histone modification, which provides a new orientation for studies on the pathogenesis of tumors.Tumors could be inhibited through the reversible nature of epigenetics to regulate the expression of tumor-related microRNA.These results show great potential in tumor therapy.The present review provides a comprehensive overview of the current literature on microRNA related to tumorous epigenetic modifications.
- MicroRNA /
- Epigenetics /
- Neoplasm /
- Therapy

HTML全文

参考文献(26)

[1]	Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215 -233. doi: 10.1016/j.cell.2009.01.002
[2]	Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets[J]. Cell, 2005, 120(1): 15-20. doi: 10.1016/j.cell.2004.12.035
[3]	Duan R Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA[J]. Hum Mol Genet, 2007, 16(9): 1124-1131. doi: 10.1093/hmg/ddm062
[4]	Ueda T, Volinia S, Okumura H. et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis[J]. Lancet Oncol, 2010, 11(2): 136-146. doi: 10.1016/S1470-2045(09)70343-2
[5]	Steinemann D, Tauscher M, Praulich I, et al. Mutations in the let-7 binding site-a mechanism of RAS activation in juvenile myelomonocytic leukemia[J]? Haematologica, 2010, 95(9): 1616. http://www.haematologica.org/cgi/reprint/95/9/1616-a.pdf
[6]	Ferdin J, Kunej T, Calin GA. MicroRNA: Genomic Association with Cancer Predisposition[J]J Assoc Genet Technol, 2011, 37(1): 11-19. http://www.ncbi.nlm.nih.gov/pubmed/21430351
[7]	Boominathan L. The guardians of the genome(p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network[J]. Cancer Metastasis Rev, 2010, 29(4): 613-639. doi: 10.1007/s10555-010-9257-9
[8]	Ibragimova I, Ibanez de Caceres I, Hoffman AM, et al. Global reactivation of epigenetically silenced genes in prostate cancer[J]. Cancer Prev Res(Phila), 2010, 3(9): 1084-1092. doi: 10.1158/1940-6207.CAPR-10-0039
[9]	Lopez J, Percharde M, Coley HM, et al. The context and potential of epigenetics in oncology[J]. Br J Cancer, 2009, 100(4): 571-577. doi: 10.1038/sj.bjc.6604930
[10]	Kurdistani SK. Histone modifications in cancer biology and prognosis[J]. Prog Drug Res, 2011, 67: 91-106. doi: 10.1007%2F978-3-7643-8989-5_5.pdf
[11]	Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence[J]. Nature, 2005, 435 (7046): 1262-1266. doi: 10.1038/nature03672
[12]	Vallot C, Stransky N, Bernard-Pierrot I, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. [J]. J Nad Cancer Inst, 2011, 103(1): 47-60. doi: 10.1093/jnci/djq470
[13]	Weber B, Stresemann C, Brueckner B, et al. Methylation of human microRNA genes in normal and neoplastic cells[J]. Cell Cycle, 2007, 6(9): 1001-1005. doi: 10.4161/cc.6.9.4209
[14]	Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells[J]. Cancer Res, 2007, 67(4): 1424-1429. doi: 10.1158/0008-5472.CAN-06-4218
[15]	Toyota M, Suzuki H, Sasaki Y. et al. Epigenetic silencing of microRNA -34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer[J]. Cancer Res, 2008, 68(11): 4123-4132. doi: 10.1158/0008-5472.CAN-08-0325
[16]	Lujambio A, Calin GA, Villanuneva A, et al. A microRNA DNA methylation signature for human cancer metastasis[J]. Proc Natl Acad Sci U S A, 2008, 105(36): 13556-13561. doi: 10.1073/pnas.0803055105
[17]	Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA -29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma[J]. Epigenetics, 2011, 6 (3): 388-394. doi: 10.4161/epi.6.3.14056
[18]	Benetti R, Gonzalo S, Jaco I, et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA medryltransferases[J]. Nat Struct Mol Biol, 2008, 15(3): 268-279. doi: 10.1038/nsmb.1399
[19]	Zhang J, Yang Y, Yang T, et al. MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity[J]. Br J Cancer, 2010, 103(8): 1215-1220. doi: 10.1038/sj.bjc.6605895
[20]	Noonan EJ, Place RF, Pookot D, et al. MiR-449a targets HDAC-1 and induces growth arrest in prostate cancer[J]. Oncogene, 2009, 28 (14): 1714-1724. doi: 10.1038/onc.2009.19
[21]	Li X, Liu J, Zhou R, et al. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation[J]. Br J Haematol, 2010, 148(1): 69-79. doi: 10.1111/j.1365-2141.2009.07920.x
[22]	Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer[J]. Int J Cancer, 2009, 125(11): 2737-2743. doi: 10.1002/ijc.24638
[23]	Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer[J]. Science, 2008, 322(5908): 1695-1699. doi: 10.1126/science.1165395
[24]	Bandres E, Bitarte N, Arias F, et al. MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells[J]. Clin Cancer Res, 2009, 15(7): 2281-2290. doi: 10.1158/1078-0432.CCR-08-1818
[25]	FujimotoJ, Kong M, LceJJ, et al. Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention[J], Cancer Prev Res(Phila), 2010, 3(8): 917 -928. doi: 10.1158/1940-6207.CAPR-10-0129
[26]	Saito Y, Liang G, Egger G, et al. Specific acnvation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chroma tin-modifying drugs in human cancer cells[J]. Cancer Cell, 2006, 9(6): 435-443. doi: 10.1016/j.ccr.2006.04.020